News Column

The Michael J. Fox Foundation and Intel Join Forces to Improve Parkinson’s Disease Monitoring and Treatment Through Advanced Technologies

August 13, 2014

  • Big data analytics and data from wearable computing offer potential to improve monitoring and treatment of Parkinsonís disease
  • The Intel-built big data analytics platform combines hardware and software technologies to provide researchers with a way to more accurately measure progression of disease symptoms

    NEW YORK & SANTA CLARA, Calif.--(BUSINESS WIRE)-- The Michael J. Fox Foundation for Parkinsonís Research (MJFF) and Intel Corporation announced today a collaboration aimed at improving research and treatment for Parkinsonís disease ó a neurodegenerative brain disease second only to Alzheimerís in worldwide prevalence. The collaboration includes a multiphase research study using a new big data analytics platform that detects patterns in participant data collected from wearable technologies used to monitor symptoms. This effort is an important step in enabling researchers and physicians to measure progression of the disease and to speed progress toward breakthroughs in drug development.

    Anonymous patient data is aggregated and analyzed for new insight into Parkinsonís disease via a new ...

    Anonymous patient data is aggregated and analyzed for new insight into Parkinsonís disease via a new partnership between Intel and the Michael J. Fox Foundation. (Photo: Business Wire)


    ďNearly 200 years after Parkinsonís disease was first described by Dr. James Parkinson in 1817, we are still subjectively measuring Parkinsonís disease largely the same way doctors did then,Ē said Todd Sherer, PhD, CEO of The Michael J. Fox Foundation. ďData science and wearable computing hold the potential to transform our ability to capture and objectively measure patientsí actual experience of disease, with unprecedented implications for Parkinsonís drug development, diagnosis and treatment.Ē

    ďThe variability in Parkinsonís symptoms creates unique challenges in monitoring progression of the disease,Ē said Diane Bryant, senior vice president and general manager of Intelís Data Center Group. ďEmerging technologies can not only create a new paradigm for measurement of Parkinsonís, but as more data is made available to the medical community, it may also point to currently unidentified features of the disease that could lead to new areas of research.Ē

    Tracking an Invisible Enemy

    For nearly two decades, researchers have been refining advanced genomics and proteomics techniques to create increasingly sophisticated cellular profiles of Parkinsonís disease pathology. Advances in data collection and analysis now provide the opportunity to expand the value of this wealth of molecular data by correlating it with objective clinical characterization of the disease for use in drug development.

    The potential to collect and analyze data from thousands of individuals on measurable features of Parkinsonís, such as slowness of movement, tremor and sleep quality, could enable researchers to assemble a better picture of the clinical progression of Parkinsonís and track its relationship to molecular changes. Wearables can unobtrusively gather and transmit objective, experiential data in real time, 24 hours a day, seven days a week. With this approach, researchers could go from looking at a very small number of data points and burdensome pencil-and-paper patient diaries collected sporadically to analyzing hundreds of readings per second from thousands of patients and attaining a critical mass of data to detect patterns and make new discoveries.

    MJFF and Intel initiated a study earlier this year to evaluate the usability and accuracy of wearable devices for tracking agreed physiological features from participants and using a big data analytics platform to collect and analyze the data. The participants (16 Parkinsonís patients and nine control volunteers) wore the devices during two clinic visits and at home continuously over four days.

    Bret Parker, 46, of New York, is living with Parkinsonís and participated in the study. ďI know that many doctors tell their patients to keep a log to track their Parkinsonís,Ē said Parker. ďI am not a compliant patient on that front. I pay attention to my Parkinsonís, but itís not everything I am all the time. The wearables did that monitoring for me in a way I didnít even notice, and the study allowed me to take an active role in the process for developing a cure.Ē

    Intel data scientists are now correlating the data collected to clinical observations and patient diaries to gauge the devicesí accuracy, and are developing algorithms to measure symptoms and disease progression.

    Later this year, Intel and MJFF plan to launch a new mobile application that enables patients to report their medication intake as well as how they are feeling. The effort is part of the next phase of the study to enable medical researchers to study the effects of medication on motor symptoms via changes detected in sensor data from wearable devices.

    Collecting, Storing and Analyzing the Data

    To analyze the volume of data, more than 300 observations per second from each patient, Intel developed a big data analytics platform that integrates a number of software components including Clouderaģ CDH* ó an open-source software platform that collects, stores, and manages data. The data platform is deployed on a cloud infrastructure optimized on Intelģ architecture, allowing scientists to focus on research rather than the underlying computing technologies. The platform supports an analytics application developed by Intel to process and detect changes in the data in real time. By detecting anomalies and changes in sensor and other data, the platform can provide researchers with a way to measure the progression of the disease objectively.

    In the near future, the platform could store other types of data such as patient, genome and clinical trial data. In addition, the platform could enable other advanced techniques such as machine learning and graph analytics to deliver more accurate predictive models that researchers could use to detect change in disease symptoms. These advances could provide unprecedented insights into the nature of Parkinsonís disease, helping scientists measure the efficacy of new drugs and assisting physicians with prognostic decisions.

    Shared Commitment to Open-Access Data

    MJFF and Intel share a commitment to increasing the rate of progress made possible by open access to data. The organizations aim to share data with the greater Parkinsonís community of physicians and researchers as well as invite them to submit their own de-identified patient and subject data for analysis. Teams may also choose to contribute de-identified patient data for inclusion in broader, population-scale studies.

    The Foundation has previously made de-identified data and bio-samples from its sponsored studies available to qualified researchers, including from individuals with a Parkinsonís-implicated mutation in their LRRK2 gene. MJFF has also opened access to resources from its landmark biomarker study the Parkinsonís Progression Markers Initiative (PPMI) since it launched in 2010. Parkinsonís scientists around the world have downloaded PPMI data more than 235,000 times to date.

    About The Michael J. Fox Foundation for Parkinsonís Research

    As the worldís largest nonprofit funder of Parkinsonís research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinsonís disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinsonís patients, business leaders, clinical trial participants, donors and volunteers.†In addition to funding more than $450 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinsonís research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinsonís disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinsonís awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world.

    For more information, visit us on the Web, Facebook, Twitter, LinkedIn and Pinterest.

    About Intel

    Intel (NASDAQ:INTC) is a world leader in computing innovation. The company designs and builds the essential technologies that serve as the foundation for the worldís computing devices.†As a leader in corporate responsibility and sustainability, Intel also manufactures the worldís first commercially available ďconflict-freeĒ microprocessors. Additional information about Intel is available at newsroom.intel.com and blogs.intel.com, and about Intelís conflict-free efforts at conflictfree.intel.com.

    Intel and the Intel logo are trademarks of Intel Corporation in the United States and other countries.

    *Other names and brands may be claimed as the property of others.





  • For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



    Source: Business Wire


    Story Tools






    HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters